Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

S3319

Sigma-Aldrich

sPLA2 inhibitor

Synonym(s):

5-(4-Benzyloxyphenyl)-4S-(7-phenylheptanoylamino)pentanoic acid, KH064

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C31H37NO4
CAS Number:
393569-31-8
Molecular Weight:
487.63
MDL number:
MFCD06411576
UNSPSC Code:
41106300
PubChem Substance ID:
24724605

Assay

≥97.5% (HPLC)

form

powder

storage condition

under inert gas

color

white

mp

133-135 °C

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

OC(=O)CC[C@@H](Cc1ccc(OCc2ccccc2)cc1)NC(=O)CCCCCCc3ccccc3

InChI

1S/C31H37NO4/c33-30(16-10-2-1-5-11-25-12-6-3-7-13-25)32-28(19-22-31(34)35)23-26-17-20-29(21-18-26)36-24-27-14-8-4-9-15-27/h3-4,6-9,12-15,17-18,20-21,28H,1-2,5,10-11,16,19,22-24H2,(H,32,33)(H,34,35)/t28-/m0/s1

InChI key

KWLUIYFCMHKLKY-NDEPHWFRSA-N

Application

sPLA2 inhibitor has been used in:
  • human lung adenocarcinoma cells in matrigel invasion assay
  • pre-treatment of cultured oligodendrocytes
  • the inhibition of secretory phospholipase A2 in lung adenocarcinoma.

sPLA2 inhibitor was used to study the effects on cell proliferation and apoptosis of lung cancer cells and oligodendrocytes.

Biochem/physiol Actions

Orally active, potent secretory Phospholipase A2 (sPLA2; Group IIa) inhibitor.
Secretory phospholipase A2 inhibitor blocks the activation of NF-κB, Akt, p38 MAPK and ERK pathways. It reduces proliferation and induces apoptosis of lung cancer cells and is a potent anti-inflammatory agent. sPLA2 inhibitor prevents deposition of collagen and has anti-fibrotic effects in hypertensive rats.
sPLA2 inhibitor is lipophilic and corresponds to a molecular weight of 487.63 Da. It regulates inflammatory responses and lipoprotein function and may be useful in treating atherosclerosis.
sPLA2 inhibitor (pla2g2a) is an orally active, potent secretory Phospholipase A2 (sPLA2; Group IIa) inhibitor. Secretory phospholipase A2 inhibitor blocks the activation of NF-KB, Akt, p38 MAPK and ERK pathways. sPLA2 inhibitor reduces proliferation and induces apoptosis of lung cancer cells and is a potent anti-inflammatory agent. sPLA2 inhibitor prevents deposition of collagen and has anti-fibrotic effects in hypertensive rats.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000054308
031M4604V
098K46071
098K4607
044K4610

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A2 inhibition
Jessica AY, et al.
The Journal of Thoracic and Cardiovascular Surgery, 143(2), 405-411 (2012)
Yanxiao Xiang et al.
PloS one, 8(10), e77909-e77909 (2013-10-17)
Neuroinflammation is involved in various central nervous system (CNS) disorders, including brain infections, ischemia, trauma, stroke, and degenerative CNS diseases. In the CNS inflammation, secretory phospholipase A₂-IIA (sPLA₂-IIA) acts as a mediator, resulting in the generation of the precursors of
Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells
Bennett DT, et al.
The Annals of Thoracic Surgery, 98(2), 439-446 (2014)
Alison L Halpern et al.
Digestive diseases and sciences, 66(3), 784-795 (2020-04-12)
Receptor tyrosine kinases of the epidermal growth factor receptor (EGFR) family such as human epidermal receptor-2 (HER2) are involved in the development and progression of esophageal adenocarcinoma (EAC). Prior studies have demonstrated that group IIa secretory phospholipase A2 (sPLA2 IIa)
Maung-Maung Thwin et al.
Arthritis research & therapy, 11(5), R138-R138 (2009-09-22)
Secretory phospholipase A2 (sPLA2) and matrix metalloproteinase (MMP) inhibitors are potent modulators of inflammation with therapeutic potential, but have limited efficacy in rheumatoid arthritis (RA). The objective of this study was to understand the inhibitory mechanism of phospholipase inhibitor from
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service